



Finnish University Hospital Orders Nexstim NBS System 5

Press release, Helsinki, 17 December 2024 at 9 AM (EET)

Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a university hospital in Finland. The customer has multiple Nexstim systems and is now acquiring an additional new one due to the growing demand for rTMS treatments.

The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus. This specific NBS system also includes therapy software, allowing the system to also be used for the treatment of major depression and chronic neuropathic pain. The system will be primarily used in psychiatry.

Mikko Karvinen, CEO of Nexstim, comments: *"We are very happy with the number of system orders received from new and existing Finnish customers this year. TMS as a treatment option for major depression continues to gain more attention in our home market, and this customer is one of the pioneers in providing TMS treatments on a larger scale in Finland. We look forward to continuing this important work with our active Finnish user base in 2025."*

Further information is available on the website www.nexstim.com, or by contacting:

Mikko Karvinen, CEO

+358 50 326 4101

mikko.karvinen@nexstim.com

About Nexstim Plc

Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.

Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

Nexstim's Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS System 5 is the only FDA cleared and CE marked navigated TMS system for presurgical mapping of the speech and motor cortices of the brain.

Nexstim's Therapy Business markets and sells the NBS System 6 which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBS 6 system is CE marked for the treatment of major depression and chronic neuropathic pain.

Nexstim shares are listed on Nasdaq First North Growth Market Finland.

For more information, please visit www.nexstim.com